Lipocine Inc. (LPCN)

Market Cap	15.42M
Revenue (ttm)	54,990
Net Income (ttm)	-12.06M
Shares Out	5.32M
EPS (ttm)	-2.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,701
Open	3.01
Previous Close	2.98
Day's Range	2.80 - 3.15
52-Week Range	2.80 - 10.34
Beta	0.97
Analysts	Buy
Price Target	33.00 (+1,037.93%)
Earnings Date	Nov 8, 2023

About LPCN

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Mahesh V. Patel Ph.D.
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: LPCN

Financial Performance

In 2022, Lipocine's revenue was $500,000, a decrease of -96.90% compared to the previous year's $16.14 million. Losses were -$10.76 million, 1595.9% more than in 2021.

Analyst Forecast

According to one analyst, the rating for LPCN stock is "Buy" and the 12-month stock price forecast is $33.0.

Price Target

$33.0

(1,037.93% upside)

Analyst Consensus: Buy